Join

Compare · BDMD vs BSX

BDMD vs BSX

Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDMD and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX carries a market cap of $60.90B.
  • Over the past year, BDMD is down 67.8% and BSX is down 39.2% - BSX leads by 28.6 points.
  • BDMD has been more active in the news (6 items in the past 4 weeks vs 3 for BSX).
  • BSX has more recent analyst coverage (25 ratings vs 0 for BDMD).
PerformanceBDMD-67.83%BSX-39.23%
2025-04-28+0.00%2026-04-24
MetricBDMDBSX
Company
Baird Medical Investment Holdings Ltd
Boston Scientific Corporation
Price
$1.85+8.19%
$62.06-5.52%
Market cap
-
$60.90B
1M return
-15.91%
-11.05%
1Y return
-67.83%
-39.23%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
News (4w)
6
3
Recent ratings
0
25
BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.